サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1211005

治療抵抗性うつ病（TRD）治療の世界市場規模調査・予測：薬剤タイプ別、流通チャネル別、地域別分析、2022-2029年

Global Treatment-resistant Depression Treatment Market Size study & Forecast, by Drug Type, by Distribution Channel and Regional Analysis, 2022-2029
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
治療抵抗性うつ病（TRD）治療の世界市場規模調査・予測：薬剤タイプ別、流通チャネル別、地域別分析、2022-2029年
出版日: 2023年01月25日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の治療抵抗性うつ病治療市場は、2021年に約15億2000万米ドルと評価され、予測期間2022-2029年には9.0％を超える健全な成長率で成長すると予想されています。

治療抵抗性うつ病（TRD）は、治療過程において少なくとも2種類の抗うつ薬の不適切な反応に起因する大うつ病性障害（MDD）の一種です。炎症系の活性化、神経伝達物質の機能不全、神経活動の異常、メランコリックな臨床的特徴、双極性、より高い心的外傷負荷などが、この障害に関連するいくつかの条件です。経口投与に比べ他の投与経路への傾斜が強まっていること、医薬品開発プロジェクトの増加、医療費の増大などが、全世界の市場需要を促進している主な要因です。

この気分障害の有病率の上昇は、市場の成長に寄与する重要な要因です。TRDは、2種類の抗うつ剤を十分な期間（通常6週間）服用しても反応がない場合に起こります。この医学的疾患の有病率が上昇した結果、治療抵抗性うつ病の治療に対する需要が高まっています。Springer社の報告によると、2021年8月には、世界中で3億人以上の人が重大なうつ病性障害に苦しんでおり、そのうちの3分の1以上が治療抵抗性うつ病であることが分かっています。したがって、疾病負担の増大は市場成長の触媒となります。さらに、研究開発活動への投資の増加や、市場の主要企業によるイニシアティブの高まりは、予測期間中にさまざまな有利な機会をもたらしています。しかし、この気分障害患者の診断と管理のためのガイドラインにおける限られた治療手段と明確性の欠如が、2022年から2029年の予測期間を通じて市場の成長を制限しています。

治療抵抗性うつ病治療の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、中南米、世界のその他の地域です。北米は、ガイドラインの増加や医薬品の承認、多額の研究開発投資、市場関係者の注目度の上昇により、収益面で市場を独占しています。一方、アジア太平洋地域は、治療抵抗性うつ病に苦しむ患者数の増加や、市場空間における気分障害の治療に関連する意識の高まりなどの要因により、予測期間中に最も高いCAGRで成長すると予想されます。

本調査の目的は、近年における様々なセグメントと国の市場規模を定義し、今後数年間の値を予測することです。本レポートは、調査対象国における産業の質的・量的側面を取り入れるよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細な情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場の潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

  • 市場スナップショット
  • 世界・セグメント別市場推定・予測、2019年～2029年
    • 治療抵抗性うつ病治療市場：地域別、2019-2029年
    • 治療抵抗性うつ病治療市場：薬物タイプ別、2019-2029年
    • 治療抵抗性うつ病治療薬市場：流通チャネル別、2019年～2029年
  • 主な動向
  • 調査手法
  • 調査前提条件

第2章 治療抵抗性うつ病治療薬の世界市場定義と範囲

  • 調査の目的
  • 市場の定義と範囲
    • 調査対象範囲
    • 産業の進化
  • 調査対象年
  • 通貨換算レート

第3章 治療抵抗性うつ病治療の世界市場力学

  • 治療抵抗性うつ病治療薬市場のインパクト分析（2019-2029年）
    • 市場促進要因
      • 治療抵抗性うつ病の有病率の上昇
      • 医薬品開発プロジェクトの増加
    • 市場の課題
      • 限られた治療手段
      • この気分障害患者の診断と管理に関するガイドラインが明確でないこと
    • 市場機会
      • 研究開発活動への投資の増加
      • 主要な市場参入企業別イニシアチブの増加

第4章 世界の治療抵抗性うつ病治療市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォースモデルへの未来的アプローチ（2019-2029年）
  • PEST分析
    • 政治的
    • 経済的
    • 社会的
    • 技術的
  • トップ投資機会
  • 主要成功戦略
  • 業界専門家別展望
  • アナリストの結論・提言

第5章 リスクアセスメント：COVID-19のインパクト

  • COVID-19が業界に与える全体的な影響の評価
  • COVID-19以前とCOVID-19以後の市場シナリオ

第6章 治療抵抗性うつ病治療の世界市場、薬物タイプ別

  • 市場スナップショット
  • 治療抵抗性うつ病治療の世界市場：薬物タイプ別実績-ポテンシャル分析
  • 治療抵抗性うつ病治療の世界市場薬剤タイプ別推定・予測2019-2029
  • 治療抵抗性うつ病治療薬市場、サブセグメント分析
    • NMDA
    • 抗うつ薬
    • 抗精神病薬
    • その他

第7章 治療抵抗性うつ病治療の世界市場：流通チャネル別

  • 市場スナップショット
  • 治療抵抗性うつ病治療薬の世界市場：流通チャネル別、実績-ポテンシャル分析
  • 治療抵抗性うつ病治療の世界市場、流通チャネル別推定・予測2019-2029
  • 治療抵抗性うつ病治療薬市場、サブセグメント分析
    • 病院内薬局
    • ドラッグストア・小売薬局
    • オンライン薬局

第8章 治療抵抗性うつ病治療薬の世界市場：地域別分析

  • 治療抵抗性うつ病治療薬市場、地域別市場スナップショット
  • 北米
    • 米国
      • 薬剤タイプ別の推定・予測、2019年～2029年
      • 流通チャネル別の推定・予測、2019年～2029年
    • カナダ
  • 欧州治療抵抗性うつ病治療薬市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他の欧州地域
  • アジア太平洋地域の治療抵抗性うつ病治療市場のスナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカの治療抵抗性うつ病治療市場スナップショット
    • ブラジル
    • メキシコ
    • その他のラテンアメリカ地域
  • 世界のその他の地域

第9章 競合情報

  • トップ市場戦略
  • 企業プロファイル
    • Eli Lilly and Company
      • 主要情報
      • 概要
      • 財務情報（データの入手状況により異なります）
      • 製品概要
      • 最近の動向
    • GlaxoSmithKline Plc
    • Pfizer Inc.
    • Janssen Global Services, LLC（Johnson & Johnson Services, Inc.）
    • AbbVie Inc.
    • AstraZeneca Plc
    • H. Lundbeck A/S
    • Sandoz International GmbH（Novartis AG）
    • Par Pharmaceutical（Endo International plc）
    • Otsuka Pharmaceutical Co., Ltd.（Otsuka Holdings Co., Ltd.）

第10章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • バリデーション
    • 出版
  • 調査属性
  • 調査の前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Treatment-resistant Depression Treatment Market, report scope
  • TABLE 2. Global Treatment-resistant Depression Treatment Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Treatment-resistant Depression Treatment Market estimates & forecasts by Drug Type 2019-2029 (USD Billion)
  • TABLE 4. Global Treatment-resistant Depression Treatment Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
  • TABLE 5. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Treatment-resistant Depression Treatment Market
  • TABLE 70. List of primary sources, used in the study of global Treatment-resistant Depression Treatment Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Treatment-resistant Depression Treatment Market, research methodology
  • FIG 2. Global Treatment-resistant Depression Treatment Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Treatment-resistant Depression Treatment Market, key trends 2021
  • FIG 5. Global Treatment-resistant Depression Treatment Market, growth prospects 2022-2029
  • FIG 6. Global Treatment-resistant Depression Treatment Market, porters 5 force model
  • FIG 7. Global Treatment-resistant Depression Treatment Market, pest analysis
  • FIG 8. Global Treatment-resistant Depression Treatment Market, value chain analysis
  • FIG 9. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Treatment-resistant Depression Treatment Market, regional snapshot 2019 & 2029
  • FIG 15. North America Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Treatment-resistant Depression Treatment Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Treatment-resistant Depression Treatment Market is valued at approximately USD 1.52 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 9.0% over the forecast period 2022-2029. Treatment-Resistant Depression (TRD) is a variety of Major Depressive Disorder (MDD) that cause due to the improper response of at least two antidepressants in the treatment process. The inflammatory system activation, neurotransmitter dysfunction, abnormal neural activity, melancholic clinical features, bipolarity, and a higher traumatic load are some conditions that are associated with this disorder. The rising inclination towards other routes of administration compared to oral administration, the increasing drug development projects, and increasing healthcare expenditure are some primary factors that are propelling the market demand across the globe.

The rise in the prevalence of this mood disorder is a key factor that is contributing to the market's growth. TRD occurs when a person hasn't reacted to two separate antidepressant doses taken for a sufficient amount of time, typically six weeks. The demand for the treatment of treatment-resistant depression has increased as a result of the rise in the prevalence of this medical disease. Springer reported that in August 2021, there are more than 300 million individuals worldwide suffer from significant depressive disorders, and over one-third of those people have depression that is treatment-resistant depression. Hence, the rising disease burden is a catalyzing factor for the market's growth. Moreover, rising investment in research and development activities, as well as the increasing initiatives by the key market players are presenting various lucrative opportunities over the forecasting years. However, the limited therapeutic measure and lack of clarity in guidelines for diagnosis and management of this mood disorder patients are restricting the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Treatment-resistant Depression Treatment Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the increasing number of guidelines and approval of drugs, along with the significant R&D investment and increasing focus of market players. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the growing patient population suffering from treatment-resistant depressive disorder, as well as increasing awareness related to the treatment of mood disorder in the market space.

Major market players included in this report are:

Eli Lilly and Company

GlaxoSmithKline Plc

Pfizer Inc.

Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)

AbbVie Inc.

AstraZeneca Plc

H. Lundbeck A/S

Sandoz International GmbH (Novartis AG)

Par Pharmaceutical (Endo International plc)

Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.)

Recent Developments in the Market:

  • In August 2022, Merck Sharp & Dohme LLC initiated the clinical trial of its Phase IIa to evaluate the efficacy and safety of the company's MK-1942 among treatment-resistant depression patients.
  • In July 2022, Novartis Pharmaceuticals declared that the company is planning to initiate a Phase 2 clinical trial of MIJ821 (ketamine) for treatment-resistant depressive disorders in September 2022.

Global Treatment-resistant Depression Treatment Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Drug Type, Distribution Channel, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Type:

NMDA

Antidepressants

Antipsychotics

Others

By Distribution Channel:

Hospital Pharmacies

Drug Stores & Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

RoLA

Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Treatment-resistant Depression Treatment Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Treatment-resistant Depression Treatment Market, by Drug Type, 2019-2029 (USD Billion)
    • 1.2.3. Treatment-resistant Depression Treatment Market, by Distribution Channel, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Treatment-resistant Depression Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Treatment-resistant Depression Treatment Market Dynamics

  • 3.1. Treatment-resistant Depression Treatment Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rise in the prevalence of treatment-resistant depression
      • 3.1.1.2. Increasing drug development projects
    • 3.1.2. Market Challenges
      • 3.1.2.1. Limited therapeutic measure
      • 3.1.2.2. Lack of clarity in guidelines for diagnosis and management of this mood disorder patients
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising investment in research and development activities
      • 3.1.3.2. Increasing initiatives by the key market players

Chapter 4. Global Treatment-resistant Depression Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Treatment-resistant Depression Treatment Market, by Drug Type

  • 6.1. Market Snapshot
  • 6.2. Global Treatment-resistant Depression Treatment Market by Drug Type, Performance - Potential Analysis
  • 6.3. Global Treatment-resistant Depression Treatment Market Estimates & Forecasts by Drug Type 2019-2029 (USD Billion)
  • 6.4. Treatment-resistant Depression Treatment Market, Sub Segment Analysis
    • 6.4.1. NMDA
    • 6.4.2. Antidepressants
    • 6.4.3. Antipsychotics
    • 6.4.4. Others

Chapter 7. Global Treatment-resistant Depression Treatment Market, by Distribution Channel

  • 7.1. Market Snapshot
  • 7.2. Global Treatment-resistant Depression Treatment Market by Distribution Channel, Performance - Potential Analysis
  • 7.3. Global Treatment-resistant Depression Treatment Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
  • 7.4. Treatment-resistant Depression Treatment Market, Sub Segment Analysis
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies

Chapter 8. Global Treatment-resistant Depression Treatment Market, Regional Analysis

  • 8.1. Treatment-resistant Depression Treatment Market, Regional Market Snapshot
  • 8.2. North America Treatment-resistant Depression Treatment Market
    • 8.2.1. U.S. Treatment-resistant Depression Treatment Market
      • 8.2.1.1. Drug Type breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. Distribution Channel breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada Treatment-resistant Depression Treatment Market
  • 8.3. Europe Treatment-resistant Depression Treatment Market Snapshot
    • 8.3.1. U.K. Treatment-resistant Depression Treatment Market
    • 8.3.2. Germany Treatment-resistant Depression Treatment Market
    • 8.3.3. France Treatment-resistant Depression Treatment Market
    • 8.3.4. Spain Treatment-resistant Depression Treatment Market
    • 8.3.5. Italy Treatment-resistant Depression Treatment Market
    • 8.3.6. Rest of Europe Treatment-resistant Depression Treatment Market
  • 8.4. Asia-Pacific Treatment-resistant Depression Treatment Market Snapshot
    • 8.4.1. China Treatment-resistant Depression Treatment Market
    • 8.4.2. India Treatment-resistant Depression Treatment Market
    • 8.4.3. Japan Treatment-resistant Depression Treatment Market
    • 8.4.4. Australia Treatment-resistant Depression Treatment Market
    • 8.4.5. South Korea Treatment-resistant Depression Treatment Market
    • 8.4.6. Rest of Asia Pacific Treatment-resistant Depression Treatment Market
  • 8.5. Latin America Treatment-resistant Depression Treatment Market Snapshot
    • 8.5.1. Brazil Treatment-resistant Depression Treatment Market
    • 8.5.2. Mexico Treatment-resistant Depression Treatment Market
    • 8.5.3. Rest of Latin America Treatment-resistant Depression Treatment Market
  • 8.6. Rest of The World Treatment-resistant Depression Treatment Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Eli Lilly and Company
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. GlaxoSmithKline Plc
    • 9.2.3. Pfizer Inc.
    • 9.2.4. Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
    • 9.2.5. AbbVie Inc.
    • 9.2.6. AstraZeneca Plc
    • 9.2.7. H. Lundbeck A/S
    • 9.2.8. Sandoz International GmbH (Novartis AG)
    • 9.2.9. Par Pharmaceutical (Endo International plc)
    • 9.2.10. Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.)

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption